ParkinsonFranceV1, PubMed, Corpus, bibRecord, 001227

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.

Identifieur interne : 001227 ( PubMed/Corpus ); précédent : 001226; suivant : 001228

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.

Auteurs : O K Hassani ; M. Mouroux ; G A Bohme ; J M Stutzmann ; J. Féger

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2001.

RBID : pubmed:11748743

English descriptors

KwdEn :
- Adrenergic Agents, Animals, Excitatory Amino Acid Antagonists (pharmacology), Functional Laterality, Male, Models, Animal, Neurons (drug effects), Neuroprotective Agents (pharmacology), Oxidopamine, Parkinson Disease (physiopathology), Parkinson Disease, Secondary (chemically induced), Rats, Rats, Sprague-Dawley, Riluzole (pharmacology), Sodium Channel Blockers (pharmacology), Substantia Nigra (drug effects), Substantia Nigra (pathology), Subthalamic Nucleus (drug effects), Subthalamic Nucleus (pathology), Subthalamic Nucleus (physiopathology).
MESH :
- chemical , pharmacology : Excitatory Amino Acid Antagonists, Neuroprotective Agents, Riluzole, Sodium Channel Blockers.
- chemical : Adrenergic Agents, Oxidopamine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Neurons, Substantia Nigra, Subthalamic Nucleus.
- pathology : Substantia Nigra, Subthalamic Nucleus.
- physiopathology : Parkinson Disease, Subthalamic Nucleus.
- Animals, Functional Laterality, Male, Models, Animal, Rats, Rats, Sprague-Dawley.

Abstract

An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.

PubMed: 11748743

Links to Exploration step

pubmed:11748743

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.</title>
<author><name sortKey="Hassani, O K" sort="Hassani, O K" uniqKey="Hassani O" first="O K" last="Hassani">O K Hassani</name>
<affiliation><nlm:affiliation>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mouroux, M" sort="Mouroux, M" uniqKey="Mouroux M" first="M" last="Mouroux">M. Mouroux</name>
</author>
<author><name sortKey="Bohme, G A" sort="Bohme, G A" uniqKey="Bohme G" first="G A" last="Bohme">G A Bohme</name>
</author>
<author><name sortKey="Stutzmann, J M" sort="Stutzmann, J M" uniqKey="Stutzmann J" first="J M" last="Stutzmann">J M Stutzmann</name>
</author>
<author><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11748743</idno>
<idno type="pmid">11748743</idno>
<idno type="wicri:Area/PubMed/Corpus">001227</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001227</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.</title>
<author><name sortKey="Hassani, O K" sort="Hassani, O K" uniqKey="Hassani O" first="O K" last="Hassani">O K Hassani</name>
<affiliation><nlm:affiliation>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mouroux, M" sort="Mouroux, M" uniqKey="Mouroux M" first="M" last="Mouroux">M. Mouroux</name>
</author>
<author><name sortKey="Bohme, G A" sort="Bohme, G A" uniqKey="Bohme G" first="G A" last="Bohme">G A Bohme</name>
</author>
<author><name sortKey="Stutzmann, J M" sort="Stutzmann, J M" uniqKey="Stutzmann J" first="J M" last="Stutzmann">J M Stutzmann</name>
</author>
<author><name sortKey="Feger, J" sort="Feger, J" uniqKey="Feger J" first="J" last="Féger">J. Féger</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents</term>
<term>Animals</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Functional Laterality</term>
<term>Male</term>
<term>Models, Animal</term>
<term>Neurons (drug effects)</term>
<term>Neuroprotective Agents (pharmacology)</term>
<term>Oxidopamine</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Riluzole (pharmacology)</term>
<term>Sodium Channel Blockers (pharmacology)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (pathology)</term>
<term>Subthalamic Nucleus (drug effects)</term>
<term>Subthalamic Nucleus (pathology)</term>
<term>Subthalamic Nucleus (physiopathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Neuroprotective Agents</term>
<term>Riluzole</term>
<term>Sodium Channel Blockers</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adrenergic Agents</term>
<term>Oxidopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurons</term>
<term>Substantia Nigra</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Substantia Nigra</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Functional Laterality</term>
<term>Male</term>
<term>Models, Animal</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11748743</PMID>
<DateCreated><Year>2001</Year>
<Month>12</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>01</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>16</Volume>
<Issue>6</Issue>
<PubDate><Year>2001</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.</ArticleTitle>
<Pagination><MedlinePgn>1110-4</MedlinePgn>
</Pagination>
<Abstract><AbstractText>An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6-OHDA-induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons.</AbstractText>
<CopyrightInformation>Copyright 2001 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassani</LastName>
<ForeName>O K</ForeName>
<Initials>OK</Initials>
<AffiliationInfo><Affiliation>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mouroux</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bohme</LastName>
<ForeName>G A</ForeName>
<Initials>GA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stutzmann</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Féger</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018663">Adrenergic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D026941">Sodium Channel Blockers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber>
<NameOfSubstance UI="D019782">Riluzole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D018663" MajorTopicYN="N">Adrenergic Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D026941" MajorTopicYN="N">Sodium Channel Blockers</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>1</Month>
<Day>26</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2001</Year>
<Month>12</Month>
<Day>19</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11748743</ArticleId>
<ArticleId IdType="pii">10.1002/mds.1219</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001227 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001227 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:11748743
   |texte=   Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:11748743" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki